Moreover as shown in Table 2, nine of sixteen (56.3%) BCL6-rearranged DH/TH-HGBL cases, and 58.3% of the BCL6-rearranged DH-HGBL cases were non-germinal center B-cell (non-GCB), while six of 12 (50.0%) patients with BCL6-rearranged DHL had Ann Arbor stages III/IV disease, suggesting that added screening for DH/TH-DLBCL with BCL6 rearrangement in patients with the non-GCB phenotype of DLBCL may aid medical decision-making and therapeutic strategy. Here, BCL6 is linked to high grade B-cell lymphoma.